CN112293737A - 欧米伽3与连翘苷结合的植物抗病毒抗炎食品补充剂 - Google Patents
欧米伽3与连翘苷结合的植物抗病毒抗炎食品补充剂 Download PDFInfo
- Publication number
- CN112293737A CN112293737A CN202011386674.1A CN202011386674A CN112293737A CN 112293737 A CN112293737 A CN 112293737A CN 202011386674 A CN202011386674 A CN 202011386674A CN 112293737 A CN112293737 A CN 112293737A
- Authority
- CN
- China
- Prior art keywords
- parts
- omega
- phillyrin
- food supplement
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 53
- KFFCKOBAHMGTMW-LGQRSHAYSA-N Forsythin Chemical compound C1=C(OC)C(OC)=CC=C1[C@H]1[C@@H](CO[C@@H]2C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC=3)[C@@H]2CO1 KFFCKOBAHMGTMW-LGQRSHAYSA-N 0.000 title claims abstract description 35
- JJVGFDTWFVSBIM-UHFFFAOYSA-N Phillyrin Natural products COc1ccc(cc1OC)C2OCC3C2COC3c4ccc(OC)c(OC5OC(CO)C(O)C(O)C5O)c4 JJVGFDTWFVSBIM-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 35
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 31
- 241000196324 Embryophyta Species 0.000 claims abstract description 25
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 19
- 239000011575 calcium Substances 0.000 claims abstract description 19
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims abstract description 18
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229920001661 Chitosan Polymers 0.000 claims abstract description 18
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims abstract description 18
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims abstract description 18
- 229940074393 chlorogenic acid Drugs 0.000 claims abstract description 18
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims abstract description 18
- 235000001368 chlorogenic acid Nutrition 0.000 claims abstract description 18
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims abstract description 18
- 150000004676 glycans Chemical class 0.000 claims abstract description 18
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 18
- 239000005017 polysaccharide Substances 0.000 claims abstract description 18
- 240000000031 Achyranthes bidentata Species 0.000 claims abstract description 10
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims abstract description 9
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 claims abstract description 9
- 239000002960 lipid emulsion Substances 0.000 claims description 16
- 229920000881 Modified starch Polymers 0.000 claims description 7
- 239000004368 Modified starch Substances 0.000 claims description 7
- 235000019426 modified starch Nutrition 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 241000700605 Viruses Species 0.000 abstract description 11
- 241000721047 Danaus plexippus Species 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 8
- 239000013589 supplement Substances 0.000 abstract description 8
- 102100039240 NACHT, LRR and PYD domains-containing protein 12 Human genes 0.000 abstract description 3
- 101710084317 NACHT, LRR and PYD domains-containing protein 12 Proteins 0.000 abstract description 3
- 239000002671 adjuvant Substances 0.000 abstract description 2
- 235000013305 food Nutrition 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 210000004989 spleen cell Anatomy 0.000 description 9
- 210000000822 natural killer cell Anatomy 0.000 description 8
- 241000427159 Achyranthes Species 0.000 description 7
- CEEMRWKKNNEQDT-UHFFFAOYSA-N Rosmanol Natural products CC(C)c1cc2C(OC(=O)C)C3OC(=O)C4(CCCC(C)(C)C34)c2c(OC(=O)C)c1OC(=O)C CEEMRWKKNNEQDT-UHFFFAOYSA-N 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- LCAZOMIGFDQMNC-FORWCCJISA-N rosmanol Chemical compound C1CCC(C)(C)[C@@H]2[C@H]3[C@@H](O)C(C=C(C(=C4O)O)C(C)C)=C4[C@]21C(=O)O3 LCAZOMIGFDQMNC-FORWCCJISA-N 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 235000021056 liquid food Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 244000144972 livestock Species 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000205585 Aquilegia canadensis Species 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 241000229722 Perilla <angiosperm> Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229940092258 rosemary extract Drugs 0.000 description 2
- 235000020748 rosemary extract Nutrition 0.000 description 2
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241000555712 Forsythia Species 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000020931 dietary conditions Nutrition 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000015639 rosmarinus officinalis Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3472—Compounds of undetermined constitution obtained from animals or plants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/358—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及食品补充剂技术领域,具体公开了欧米伽3与连翘苷结合的植物抗病毒抗炎食品补充剂。欧米伽3与连翘苷结合的植物抗病毒抗炎食品补充剂,包括下列组分及各组分的重量份数配比:连翘苷50~70份、欧米伽3 20~30份、牛膝多糖4~10份、绿原酸1~5份、离子钙1~5份、壳聚糖1~3份、迷迭香酚1~3份。本发明以中医药“君臣佐使”原理结合而配伍的:连翘苷为“君1”,绿原酸为“君2”,牛膝多糖为“君3”,而欧米伽3为“臣”,壳聚糖为“佐”,离子钙和迷迭香酚为“使”。食品补充剂中的各组分各自发挥主治功能,对于人体来说,使人体补充天然的植物抗病毒抗炎成分,能够起到协同增效的作用,辅助人体抵抗病毒侵袭。
Description
技术领域
本发明涉及食品技术领域,特别涉及欧米伽3与连翘苷结合的植物抗病毒抗炎食品补充剂。
背景技术
随着生活条件改善,人们的饮食条件有很大的提高。但现代人往往由于缺乏运动而体质变差,很容易就会受到病毒的侵袭,进而身体产生各种症状。一般到医院就诊之后,基本都要吃一段时间的药物。但是药三分毒,对于体质虚弱的人来说,吃药往往会导致健康受损,不利于症状的痊愈。从植物中提取天然抗病毒抗炎有效成分并组合形成植物抗病毒抗炎食品补充剂,通过口服或添加到食品中,在食品中走出抗病毒的这条路,是主要研究方向。
发明内容
为了克服现有技术中存在的不足,本发明提供欧米伽3与连翘苷结合的植物抗病毒抗炎食品补充剂,解决体质虚弱人群长期吃药,不利于身体症状痊愈,同时不能很好地抗病毒抗炎的问题。
本发明解决其技术问题所采用的技术方案是:欧米伽3与连翘苷结合的植物抗病毒抗炎食品补充剂,包括下列重量份数的各组分:连翘苷50~70份、欧米伽3 20~30份、牛膝多糖4~10份、绿原酸 1~5份、离子钙1~5份、壳聚糖1~3份、迷迭香酚1~3份。
优选的,所述欧米伽3与连翘苷结合的植物抗病毒抗炎食品补充剂,包括下列重量份数的各组分:连翘苷55~65份、欧米伽3 20~25份、牛膝多糖6~9份、绿原酸 1~3份、离子钙1~3份、壳聚糖1~2份、迷迭香酚1~2份。
优选的,以食品级变性淀粉为载体,将上述食品补充剂的各组分混合并配制成片状或粉末状。
优选的,以欧米伽3形成的脂肪乳剂为载体,将上述食品补充剂的各组分混合并配制成液体。
本发明与现有技术相比,具有以下有益效果:本发明以中医药“君臣佐使”原理结合而配伍的,连翘苷为“君1”,绿原酸为“君2”,牛膝多糖为“君3”,而欧米伽3 为“臣”,壳聚糖为“佐”,离子钙和迷迭香酚为“使”。各组分各自发挥主治功能,对于人体来说,能够起到协同增效的作用。离子钙和迷迭香提取物具有较强的抗氧化活性,对本食品补充剂起到防腐的作用,这样就避免用到食品加工中经常添加的防腐剂。将本发明的食品补充剂通过口服或添加到食品中,使人体补充天然的植物抗病毒抗炎成分,辅助人体抵抗病毒侵袭,是一种帮助人体预防病毒性感染的抗病毒抗炎产品。
附图说明
图1为本发明实施例中IFN-α刺激前的脾脏细胞NK活性对比图;
图2为本发明实施例中IFN-α刺激后的脾脏细胞NK活性对比图。
具体实施方式
下面对本发明的具体实施方式作进一步说明。在此需要说明的是,对于这些实施方式的说明用于帮助理解本发明,但并不构成对本发明的限定。
本发明的主要组分为连翘苷、欧米伽3、牛膝多糖、绿原酸、离子钙、壳聚糖、迷迭香酚,要求均为医用食品级天然植物提取物或生物提取物。
需要说明的是:
连翘苷为木犀科植物连翘的干燥果实的提取物,功能主治清热解毒,消肿散结,常用于风热感冒,对冠状病毒有明显的抑制作用。
绿原酸是金银花的提取物,是金银花主要抗菌、抗病毒有效药理成分之一。绿原酸是一种重要的生物活性物质,具有抗菌、抗病毒、增高白血球等作用。
在本发明中的欧米伽3包括α-亚麻酸和DHA,只用提取自紫苏籽的α-亚麻酸和提取自海藻的DHA作为选项。因紫苏籽尚未转基因种植,微藻尚未被重金属污染。特别是微藻含有二十二碳六烯酸(DHA),是ω-3不饱和脂肪酸家族中的重要成员。同时,欧米伽3作为动物体细胞膜的重要组成部分,当动物体中的欧米伽3缺少时,细胞膜的活动通道受阻碍,不能使有效物质进入细胞内。
牛膝多糖是从中药牛膝根中提取的一种生物活性多糖,具有提高巨噬细胞吞噬功能和动物体免疫力的作用。
壳聚糖为天然多糖甲壳素脱除部分乙酰基的产物,具有生物降解性、生物相容性、无毒性、抑菌、抗癌、降脂、增强免疫等多种生理功能;本发明中的壳聚糖采用相对分子质量为10000的壳聚糖。
离子钙是一种水溶性的活性钙离子剂,本发明中的离子钙是采用低温提取技术从贝壳中提取的保持活性的离子钙。
迷迭香酚是从迷迭香花和叶子中提取出来的,提取物主要有效成分为迷迭香酚。迷迭香酚具有较强的抗氧化活性,在防止油脂氧化方面具有明显效果。
以下列举本发明用于辅助动物体抗病毒抗炎的食品补充剂的几种实施例:
实施例1:
欧米伽3与连翘苷结合的植物抗病毒抗炎食品补充剂,包括下列组分及各组分的重量份数配比:连翘苷60份、欧米伽3 25份、牛膝多糖7份、绿原酸3份、离子钙3份、壳聚糖1份、迷迭香酚1份。以食品级变性淀粉为载体,将上述食品补充剂的各组分混合,配制成片状或粉末状的食品补充剂;或以欧米伽3形成的脂肪乳剂为载体,经成熟的工艺,制成液体的食品补充剂。
实施例2:
欧米伽3与连翘苷结合的植物抗病毒抗炎食品补充剂,包括下列组分及各组分的重量份数配比:连翘苷50份、欧米伽3 20份、牛膝多糖4份、绿原酸 1份、离子钙1份、壳聚糖1份、迷迭香酚1份。以食品级变性淀粉为载体,将上述食品补充剂的各组分混合,配制成片状或粉末状的食品补充剂;或以欧米伽3形成的脂肪乳剂为载体,经成熟的工艺,制成液体的食品补充剂。
实施例3:
欧米伽3与连翘苷结合的植物抗病毒抗炎食品补充剂,包括下列组分及各组分的重量份数配比:连翘苷70份、欧米伽3 30份、牛膝多糖10份、绿原酸5份、离子钙5份、壳聚糖3份、迷迭香酚3份。以食品级变性淀粉为载体,将上述食品补充剂的各组分混合,配制成片状或粉末状的食品补充剂;或以欧米伽3形成的脂肪乳剂为载体,经成熟的工艺,制成液体的食品补充剂。
实施例4:
欧米伽3与连翘苷结合的植物抗病毒抗炎食品补充剂,包括下列组分及各组分的重量份数配比:连翘苷55份、欧米伽3 23份、牛膝多糖6份、绿原酸 2份、离子钙2份、壳聚糖2份、迷迭香酚2份。以食品级变性淀粉为载体,将上述食品补充剂的各组分混合,配制成片状或粉末状的食品补充剂;或以欧米伽3形成的脂肪乳剂为载体,经成熟的工艺,制成液体的食品补充剂。
实施例5:
欧米伽3与连翘苷结合的植物抗病毒抗炎食品补充剂,包括下列组分及各组分的重量份数配比:连翘苷65份、欧米伽3 28份、牛膝多糖8份、绿原酸4份、离子钙4份、壳聚糖2份、迷迭香酚2份。以食品级变性淀粉为载体,将上述食品补充剂的各组分混合,配制成片状或粉末状的食品补充剂;或以欧米伽3形成的脂肪乳剂为载体,经成熟的工艺,制成液体的食品补充剂。
为验证本发明的效果,以最佳的实施例的食品补充剂(以下将欧米伽3与连翘苷结合的植物抗病毒抗炎食品补充剂简称食品补充剂)进行以下具体试验实例:
通过对小鼠施用含有该食品补充剂的饲料所进行的NK细胞活性的测定(在生物体细胞在感知到病毒感染时,会产生以IFN-α(干扰素)为代表的I型IFN,I型IFN将NK细胞进行活化,并通过NK细胞来攻击被病毒感染的细胞,消灭病毒。因而,增强基于病毒感知的NK细胞活性的程度,便可抑制病毒增殖,防止感染的扩大)。
选取20只BALB/c小鼠(雌性、5周龄),正常饲料饲养1周后,测定其体重,以n=10分为平均体重大致相同的2组(平均体重:约31g)。一组作为对照组,饲养 3g/天的饲料(将0.5ml欧米伽3形成的脂肪乳剂添加进饲料中),另一组饲养3g/天的饲料(将0.5ml以欧米伽3形成的脂肪乳剂为载体的食品补充剂添加进饲料中)进行3周饲养。其后将小鼠安乐死,采集脾脏细胞。
使用FACS(荧光活化细胞分拣器)进行NK细胞活性的测定,将制备的脾脏细胞,以YAC-1细胞作为靶细胞。同时脾脏细胞与YAC-1细胞的比率设定为50:1。在IFN-α(干扰素)刺激前后的各时刻分别测定脾脏细胞的NK活性。IFN-α刺激通过利用以1000单位/ml添加有IFN-α(干扰素)的培养基对接种至96孔(圆底)微孔板中的脾脏细胞进行4小时培养来进行。
图 1和图2中,“欧米伽3”是以欧米伽3形成的脂肪乳剂饲养组(对照组)。另外,“食品补充剂”是以欧米伽3形成的脂肪乳剂为载体的食品补充剂饲养组。对IFN-α(干扰素)刺激前后对所得到的结果进行比较:在未利用IFN-α对脾脏细胞进行刺激的情况下,以欧米伽3形成的脂肪乳剂为载体的食品补充剂饲养组的NK细胞活性与以欧米伽3形成的脂肪乳剂饲养组(对照组)相比无明显变化(图1)。对利用IFN-α对脾脏细胞刺激后的NK细胞活性进行比较后,以欧米伽3形成的脂肪乳剂为载体的食品补充剂饲养组的NK细胞活性相比于以欧米伽3形成的脂肪乳剂饲养组(对照组)有明显上升(图2)。从而表明,该食品补充剂通过使生物体在感染病毒时所产生的对IFN-α产生应答的NK细胞活性上升得到增强而显示出抗病毒活性。
本发明就是根据理论与实践,以中医药“君臣佐使”原理结合而配伍的。连翘苷为“君1”,作为一种天然的植物抗生素,功能主治清热解毒,常用于风热感冒,对冠状病毒有明显的抑制作用;绿原酸为“君2”,作为一种水溶性酚类化合物,在植物界中分布广泛,展现出较强的生物活性和多方面的药理作用,也具有较强的抗病毒抗炎作用;牛膝多糖为“君3”,具有提高巨噬细胞吞噬功能的作用,提高免疫力,与连翘苷和绿原酸共同结合,起到协同增效的作用;而欧米伽3 为“臣”,作为一种不饱和脂肪酸,是细胞膜的营养物质,当动物体中的欧米伽3缺乏时,细胞膜的活动通道受阻碍,不能使有效物质进入细胞内。欧米伽3充足时,细胞膜的活动通道正常运转,能够使连翘苷、绿原酸、牛膝多糖等抗病毒抗炎成分进入细胞内部,在保护细胞膜的同时进一步协助抑制病毒的存在;同时,组分中的壳聚糖为“佐”,是作为肠道中有益细菌的营养物质,起到调节肠道微生态平衡,帮助更好地吸收食品中的营养物质,提升免疫机能,提高免疫力;离子钙和迷迭香提取物为“使”,都是天然提取物,具有较强的抗氧化活性,对本食品补充剂起到防腐的作用,这样就避免用到食品加工中经常添加的防腐剂。本发明充分发挥了中医药“君臣佐使”的协调作用,配方加大抗病毒、抑制炎症的作用,同时注重欧米伽3脂肪酸保护细胞膜、肠粘膜、呼吸道粘膜及全身细胞膜的作用。用壳聚糖加强肠道吸收,用天然离子钙和迷迭香酚防腐,使产出品成为天然的“抗生素”食品补充剂。食品补充剂中的各组分各自发挥主治功能,使动物体补充天然的植物抗病毒抗炎成分,能够起到协同增效的作用,辅助抵抗病毒侵袭。
上述配方产成品可为:粉末、液体(乳液、脂肪乳)、固体、结晶体(果冻、晶粉)等形态,适用于各类食品、动物食品及饲料。依据用量的大小,分别适量用于人体及动物及牲畜(产成品中予以说明)。片状的食品补充剂可用于正常食品(包括饲料)添加,也可依据量的大小在饮食之前单独口服;粉末状和液体的食品补充剂,可以在常规食品(包括饲料)中按比例加入。通过食品(包括饲料)加入并摄入,使人体(包括动物、牲畜)补充天然的植物抗病毒抗炎物质,辅助人体(包括动物、牲畜)抵抗病毒侵袭,是一种帮助人体(包括动物、牲畜)预防病毒性感染的抗病毒、抗炎产品,是天然抗病毒、抗炎食品补充剂。
以上对本发明的实施方式作了详细说明,但本发明不限于所描述的实施方式。对于本领域的技术人员而言,在不脱离本发明原理和精神的情况下,对这些实施方式进行多种变化、修改、替换和变型,仍落入本发明的保护范围内。
Claims (4)
1.欧米伽3与连翘苷结合的植物抗病毒抗炎食品补充剂,其特征在于,包括下列重量份数的各组分:
连翘苷 50~70份;
欧米伽3 20~30份;
牛膝多糖 4~10份;
绿原酸 1~5份;
离子钙 1~5份;
壳聚糖 1~3份;
迷迭香酚 1~3份。
2.根据权利要求1所述的欧米伽3与连翘苷结合的植物抗病毒抗炎食品补充剂,其特征在于,包括下列重量份数的各组分:
连翘苷 55~65份;
欧米伽3 20~25份;
牛膝多糖 6~9份;
绿原酸 1~3份;
离子钙 1~3份;
壳聚糖 1~2份;
迷迭香酚 1~2份。
3.根据权利要求1所述的欧米伽3与连翘苷结合的植物抗病毒抗炎食品补充剂,其特征在于:以食品级变性淀粉为载体,将上述食品补充剂的各组分混合并配制成片状或粉末状。
4.根据权利要求1所述的欧米伽3与连翘苷结合的植物抗病毒抗炎食品补充剂,其特征在于:以欧米伽3形成的脂肪乳剂为载体,将上述食品补充剂的各组分混合并配制成液体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011386674.1A CN112293737A (zh) | 2020-12-01 | 2020-12-01 | 欧米伽3与连翘苷结合的植物抗病毒抗炎食品补充剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011386674.1A CN112293737A (zh) | 2020-12-01 | 2020-12-01 | 欧米伽3与连翘苷结合的植物抗病毒抗炎食品补充剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112293737A true CN112293737A (zh) | 2021-02-02 |
Family
ID=74487408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011386674.1A Pending CN112293737A (zh) | 2020-12-01 | 2020-12-01 | 欧米伽3与连翘苷结合的植物抗病毒抗炎食品补充剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112293737A (zh) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1682711A (zh) * | 2005-03-07 | 2005-10-19 | 成都厚发科技开发有限公司 | 具有清热解毒作用的药物组合物 |
CN1823936A (zh) * | 2005-12-31 | 2006-08-30 | 天津生机集团 | 抗病毒药物组合物、制备方法及用途 |
CN101496585A (zh) * | 2008-01-31 | 2009-08-05 | 郑善良 | 欧米加3复合食品补充剂 |
CN101890030A (zh) * | 2009-05-18 | 2010-11-24 | 江苏中康药物科技有限公司 | 抗菌、抗病毒、抗氧化及抗色素沉积的组合物 |
CN102919385A (zh) * | 2012-11-20 | 2013-02-13 | 曾晓飞 | 一种富含欧米伽3复配食品补充剂的新型食品 |
CN103766909A (zh) * | 2012-10-17 | 2014-05-07 | 曾晓飞 | 一种富含欧米伽3复配食品补充剂的新型食品 |
CN104606213A (zh) * | 2013-11-05 | 2015-05-13 | 亚宝药业集团股份有限公司 | 一种抗流感病毒的药物组合物 |
CN104856055A (zh) * | 2015-05-20 | 2015-08-26 | 曾晓飞 | 一种以虾青素与欧米伽3结合的食品补充剂 |
CN105362283A (zh) * | 2014-08-07 | 2016-03-02 | 富力 | 连翘苷/连翘脂素组合物在制备缓解或/和治疗病毒性疾病的药物或保健品中的应用 |
CN105796861A (zh) * | 2015-04-23 | 2016-07-27 | 富力 | 连翘苷、连翘苷衍生物、连翘苷与连翘脂素组合物在制备提高免疫功能的药物中的应用 |
-
2020
- 2020-12-01 CN CN202011386674.1A patent/CN112293737A/zh active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1682711A (zh) * | 2005-03-07 | 2005-10-19 | 成都厚发科技开发有限公司 | 具有清热解毒作用的药物组合物 |
CN1823936A (zh) * | 2005-12-31 | 2006-08-30 | 天津生机集团 | 抗病毒药物组合物、制备方法及用途 |
CN101496585A (zh) * | 2008-01-31 | 2009-08-05 | 郑善良 | 欧米加3复合食品补充剂 |
CN101890030A (zh) * | 2009-05-18 | 2010-11-24 | 江苏中康药物科技有限公司 | 抗菌、抗病毒、抗氧化及抗色素沉积的组合物 |
CN103766909A (zh) * | 2012-10-17 | 2014-05-07 | 曾晓飞 | 一种富含欧米伽3复配食品补充剂的新型食品 |
CN102919385A (zh) * | 2012-11-20 | 2013-02-13 | 曾晓飞 | 一种富含欧米伽3复配食品补充剂的新型食品 |
CN104606213A (zh) * | 2013-11-05 | 2015-05-13 | 亚宝药业集团股份有限公司 | 一种抗流感病毒的药物组合物 |
CN105362283A (zh) * | 2014-08-07 | 2016-03-02 | 富力 | 连翘苷/连翘脂素组合物在制备缓解或/和治疗病毒性疾病的药物或保健品中的应用 |
CN105796861A (zh) * | 2015-04-23 | 2016-07-27 | 富力 | 连翘苷、连翘苷衍生物、连翘苷与连翘脂素组合物在制备提高免疫功能的药物中的应用 |
CN104856055A (zh) * | 2015-05-20 | 2015-08-26 | 曾晓飞 | 一种以虾青素与欧米伽3结合的食品补充剂 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mayell | Maitake extracts and their therapeutic potential-a review | |
Hoseinifar et al. | Can dietary jujube (Ziziphus jujuba Mill.) fruit extract alter cutaneous mucosal immunity, immune related genes expression in skin and growth performance of common carp (Cyprinus carpio)? | |
US20190008907A1 (en) | Compositions for management of wounds, skin diseases, dehydration, chronic diseases, and respiratory diseases | |
AU2011282200B2 (en) | Anti-viral properties of Aloe vera and Acquired Immune Deficiency Syndrome (AIDS) treatment | |
Farag et al. | Propolis: Properties and composition, health benefits and applications in fish nutrition | |
JP4839436B2 (ja) | 消化管粘膜保護剤、カベオリン遺伝子発現促進剤及び抗ストレス剤 | |
Rahiman et al. | Oleuropein and oleic acid: A novel emerging dietary target for human chronic diseases | |
KR101829637B1 (ko) | 참옻나무 목심 추출물을 함유하는 항암치료 부작용에 따른 소화기능장애, 백혈구 감소증 및 골수부전증의 개선, 예방 또는 치료용 조성물 | |
CN105726661A (zh) | 用于清除畜禽体内毒素的复方制剂及其制备方法 | |
Sumera et al. | The micronutrient combination with immune-enhancing effects | |
CN112293737A (zh) | 欧米伽3与连翘苷结合的植物抗病毒抗炎食品补充剂 | |
Ramadhan | Hematological Alterations Induced by Zinc Oxide Nanoparticles and Preventive Role of Moringa Oleifera: In vivo. | |
DE202007008818U1 (de) | Zusammensetzung zur Behandlung von Infekten | |
KR20220101675A (ko) | 화학적으로 유도된 말초신경병증 및 이의 증상의 예방 및/또는 치료를 위한 스피루리나 수용액 추출물, 조성물 및 이의 용도 | |
Orsolic et al. | Antimetastatic effect of honey. | |
JP2003104901A (ja) | 健康指向性組成物 | |
CN107296858B (zh) | 一种抗细菌感染药物组合物及其应用 | |
Korkmaz et al. | The Potential Antiviral Activity of Inositol (Vitamin B8) as a Dietary Supplement in Human and Animal Nutrition | |
El-Said et al. | Therapeutic, chemo-sensitizing, protective effects of natural products against cancerous cells: Preclinical and clinical studies | |
CN106983771B (zh) | 防治海马头部溃烂病的药物及组合物 | |
CN115919825A (zh) | 一种油溶性蚁酸作抗病毒、抗菌原料的药剂、及其制备方法 | |
CN105395797A (zh) | 一种治疗梭鱼细菌性烂鳃病的中西复方药物组合物 | |
Lopez et al. | Pharmacology and Bio-medicinal properties of Chitin and its derivative | |
CN104922144B (zh) | 一种具有升高白细胞作用的药物组合物及应用 | |
Asimi et al. | Immunomodulatory and growth response of L. rohita to dietary fortification of clove and/cardamom extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |